Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemcentrx IncfiledCriticalStemcentrx Inc
Publication of AR101757A1publicationCriticalpatent/AR101757A1/en
Anticuerpos anti-MF12 y conjugados de droga anticuerpo, y los métodos para usar tales anticuerpos anti-MF12 y conjugados de fármaco anticuerpo para tratar el cáncer. Ácido nucleico, vector, célula huésped, composición farmacéutica.Anti-MF12 antibodies and antibody drug conjugates, and methods for using such anti-MF12 antibodies and antibody drug conjugates to treat cancer. Nucleic acid, vector, host cell, pharmaceutical composition.
ARP150102824A2014-09-052015-09-03
ANTI-MFI2 ANTIBODIES AND METHODS OF USE
AR101757A1
(en)
bispecific antibody, pharmaceutical composition, use of bispecific antibody, nucleic acid sequence, expression vector, host cell and method of producing an antibody
Compounds derived from 2-oxy-2-phenyl-n-5-pyrrolidin-3-ylamino-1,3,4-thiadiazol-2-ylacetamide, pharmaceutical composition gls1 inhibitors and their use to treat cancer.